Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. (Q30542081)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

anaplastic oligodendroglioma

15 February 2020

main subject

phase III clinical trial

0 references

0 references

1 reference

1 reference

based on heuristic

inferred from title

adult oligodendroglioma

1 reference

based on heuristic

inferred from title

author

Normand J. Laperriere

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Gregory Cairncross

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Meihua Wang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Edward Shaw

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Robert Jenkins

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

David Brachman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Jan Buckner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Karen Fink

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Luis Souhami

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Walter Curran

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

language of work or name

English

0 references

publication date

15 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Oncology

15 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

337-343

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

Initial treatment patterns over time for anaplastic oligodendroglial tumors

15 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Update on molecular findings, management and outcome in low-grade gliomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

IDH1 and IDH2 mutations in gliomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Malignant gliomas in adults

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Survey of treatment recommendations for anaplastic oligodendroglioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

MGMT gene silencing and benefit from temozolomide in glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Successful chemotherapy for recurrent malignant oligodendroglioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Successful chemotherapy for newly diagnosed aggressive oligodendroglioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Influence of unrecognized molecular heterogeneity on randomized clinical trials

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

Response criteria for phase II studies of supratentorial malignant glioma

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3732012

26 November 2018

Identifiers

DOI

10.1200/JCO.2012.43.2674

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

PubMed publication ID

23071247

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23071247%20AND%20SRC:MED&resulttype=core&format=json